Literature DB >> 22019566

Chemokines and cytokines in neuroinflammation leading to neuropathic pain.

Norikazu Kiguchi1, Yuka Kobayashi, Shiroh Kishioka.   

Abstract

There has been recent evidence showing the correlation between neuroinflammation owing to the chemokine-cytokine network and neuropathic pain. Chemokines and cytokines are derived from several types of cells in the peripheral and central nervous systems following nerve injury, and are largely involved in the pathogenesis of neuropathic pain. The roles of typical inflammatory cytokines such as interleukin-1β have become the recent center of attention. There is growing evidence that inflammatory chemokines (CCL2, CCL3, and fractalkine) play pivotal roles in neuropathic pain. Further investigations concerning the functions of the chemokine-cytokine network-mediated regulation of neuroinflammation may lead to novel therapeutic strategies against intractable neuropathic pain. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22019566     DOI: 10.1016/j.coph.2011.10.007

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  88 in total

1.  Experimental autoimmune prostatitis induces microglial activation in the spinal cord.

Authors:  Larry Wong; Joseph D Done; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Prostate       Date:  2014-09-27       Impact factor: 4.104

2.  The opioid antagonist, β-funaltrexamine, inhibits NF-κB signaling and chemokine expression in human astrocytes and in mice.

Authors:  Randall L Davis; Subhas Das; J Thomas Curtis; Craig W Stevens
Journal:  Eur J Pharmacol       Date:  2015-05-22       Impact factor: 4.432

3.  In vivo and systems biology studies implicate IL-18 as a central mediator in chronic pain.

Authors:  Kiran Vasudeva; Yoram Vodovotz; Nabil Azhar; Derek Barclay; Jelena M Janjic; John A Pollock
Journal:  J Neuroimmunol       Date:  2015-04-28       Impact factor: 3.478

4.  Pro-inflammatory cytokines involvement in the hesperidin antihyperalgesic effects at peripheral and central levels in a neuropathic pain model.

Authors:  A I Carballo-Villalobos; M E González-Trujano; N Alvarado-Vázquez; F J López-Muñoz
Journal:  Inflammopharmacology       Date:  2017-03-06       Impact factor: 4.473

5.  The role of G-protein receptor 84 in experimental neuropathic pain.

Authors:  Louise S C Nicol; John M Dawes; Federica La Russa; Athanasios Didangelos; Anna K Clark; Clive Gentry; John Grist; John B Davies; Marzia Malcangio; Stephen B McMahon
Journal:  J Neurosci       Date:  2015-06-10       Impact factor: 6.167

6.  Altered expression of glial markers, chemokines, and opioid receptors in the spinal cord of type 2 diabetic monkeys.

Authors:  Norikazu Kiguchi; Huiping Ding; Christopher M Peters; Nancy D Kock; Shiroh Kishioka; J Mark Cline; Janice D Wagner; Mei-Chuan Ko
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2016-10-14       Impact factor: 5.187

7.  Rapamycin ameliorates neuropathic pain by activating autophagy and inhibiting interleukin-1β in the rat spinal cord.

Authors:  Tao Feng; Qin Yin; Ze-Lin Weng; Jian-Cheng Zhang; Kun-Feng Wang; Shi-Ying Yuan; Wei Cheng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-12-06

Review 8.  Interactions Between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma on Neuroinflammation, Demyelination, and Remyelination in Multiple Sclerosis.

Authors:  Alexandre Vallée; Jean-Noël Vallée; Rémy Guillevin; Yves Lecarpentier
Journal:  Cell Mol Neurobiol       Date:  2017-09-13       Impact factor: 5.046

9.  Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists.

Authors:  Alysia N Lozano-Ondoua; Katherine E Hanlon; Ashley M Symons-Liguori; Tally M Largent-Milnes; Josh J Havelin; Henry L Ferland; Anupama Chandramouli; Mabel Owusu-Ankomah; Tijana Nikolich-Zugich; Aaron P Bloom; Juan Miguel Jimenez-Andrade; Tamara King; Frank Porreca; Mark A Nelson; Patrick W Mantyh; Todd W Vanderah
Journal:  J Bone Miner Res       Date:  2013-01       Impact factor: 6.741

10.  MiR-19a targets suppressor of cytokine signaling 1 to modulate the progression of neuropathic pain.

Authors:  Conghui Wang; Qi Jiang; Min Wang; Dong Li
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.